Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruboxistaurin in Diabetic Peripheral Neuropathy
NCT00044421Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2002
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in diabetic peripheral neuropathy (DPN) comparing Ruboxistaurin mesylate with Placebo (2 arms). Primary endpoint: Reduction in the progression of Diabetic Peripheral Neuropathy measured by composite score. Started Jul 2002; status: completed.
02
Drugs
ruboxistaurin
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT00044421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044421.